Clinical trials: Zoster
Acute Herpes Zoster
A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers
This study is designed to evaluate the potential for a PK drug-drug interaction between FV-100 and ritonavir. The study is a single-center, open-label, randomized, 2-way crossover design in healthy volunteers.
- Trial name
- NCT02322957
- Testing
- FV-100
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ContraVir Pharmaceuticals, Inc.
Herpes Zoster
Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older
The purpose of this study is to assess the safety and immunogenicity of the GSK Biologicals' HZ vaccine 1437173A administered on either a 0,2-; 0,6- or 0,12-month schedule in adults aged 50 years or above, as the immunogenicity…
- Trial name
- NCT01751165
- Testing
- Herpes zoster vaccine GSK1437173A
- Where
- 4 sites in United States, Estonia
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (MMRVNS) vaccine will produce an immune response.
- Conditions
- Measles, Mumps, Rubella, Varicella (Chickenpox)
- Trial name
- MMRVNS 20-002 (NCT07742644)
- Testing
- MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
- Where
- 62 sites in United States, Argentina and 4 more
- Volunteers
- 1,860 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox
Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old
This is a cross-over, open-label, single-group study. The study subjects were children 12 months to 12 years of age who will be vaccinated with a single dose.
- Trial name
- NCT04384016
- Testing
- Skyvaricella Injection
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Vietnam Military Medical University
Healthy
Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine
The re-activating nature of Varicella Zoster Virus (VZV) may allow life long boosting when used as a vaccine vector in conjunction with HIV to generate durable immunity systemically and at the mucosa.
- Trial name
- KAVI-VZV-001 (NCT02514018)
- Testing
- Live-attenuated varicella-zoster virus vaccine
- Where
- Kenya
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Postherpetic Neuralgia
New Topical Treatment for Continued Pain After Shingles
Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as…
- Trial name
- NCT00566904
- Testing
- Epikeia coatings with aspirin, Epikeia coatings with lidocaine, Epikeia coatings alone
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Biomedical Development Corporation
Varicella, Herpes Zoster
A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)
The purpose of these continuing post-licensure studies is to evaluate the long-term effectiveness of VARIVAX® [Varicella Virus Vaccine Live (Oka/Merck)] and to assess the impact of the vaccine on the epidemiology of varicella and…
- Trial name
- NCT01077804
- Volunteers
- 7,585 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cutaneous Manifestations, Skin Manifestations
Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019.
- Conditions
- Cutaneous Manifestations, Skin Manifestations, COVID-19, COVID-19 Pneumonia
- Trial name
- NCT05094687
- Where
- Pakistan
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre
Herpes Zoster
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
Background: Shingles is a painful, blistering rash caused by the same virus that causes chickenpox. Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18.
- Trial name
- NCT05580458
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years.
- Trial name
- NCT06335849
- Testing
- LYB004 25µg, LYB004 50µg, SHINGRIX
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Herpes Zoster, Postherpetic Neuralgia
Shingles Prevention Study
The incidence and severity of HZ (or shingles), as well as the frequency and severity of its complications, increases markedly with increasing age. More than half of all cases occur in persons over the age of 60.
- Trial name
- SPS (NCT00007501)
- Testing
- Varicella-zoster vaccine
- Where
- 22 sites in United States
- Volunteers
- 38,456 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Herpes Zoster
Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)
PRIMARY OBJECTIVES Two co-primary objectives are: To demonstrate that the immunogenicity of ZOSTAVAX administered by intramuscular route (IM) is non-inferior to ZOSTAVAX administered by subcutaneous route (SC) To demonstrate that…
- Trial name
- NCT01391546
- Testing
- ZOSTAVAX
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older
This study evaluates the safety and immunogenicity of live attenuated vaccine in adults aged 50 years and older. Half of participants will receive high doses of the vaccine,while the other half will receive low doses of the…
- Trial name
- NCT02526745
- Testing
- the vaccine with high doses of virus content between 4.7～5.0 lgPFU, the vaccine with low doses of virus content between 4.7～5.0 lgPFU, the vaccine with high doses of virus content between 4.3～5.0 lgPFU
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention
Herpes Zoster
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07354659
- Testing
- A zoster mRNA vaccine SYS6017, Active Comparator Vaccine
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Herpes Zoster
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
The purpose of this study was to assess vaccine efficacy (VE), ability to generate immune response and safety of two doses of the recombinant subunit zoster vaccine (RZV) for prevention of Herpes Zoster (HZ) in Chinese adults…
- Trial name
- NCT04869982
- Testing
- RZV
- Where
- 6 sites in China
- Volunteers
- 6,138 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another…
- Trial name
- NCT00231816
- Testing
- ZOSTAVAX™ (concomitant), Comparator: Influenza Vaccine, ZOSTAVAX™ (Nonconcomitant)
- Volunteers
- 763 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Herpes Zoster Vaccine
Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older
The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
- Trial name
- NCT06851832
- Testing
- Recombinant zoster vaccine(CHO cell)(low adjuvant), Recombinant Zoster Vaccine (CHO cell), Zoster Vaccine, Live
- Where
- China
- Volunteers
- 960 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Shingles
Optimal Timing of Zoster Vaccine After Zoster Illness
The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.
- Trial name
- NCT02704572
- Testing
- Zostavax
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Herpes Zoster
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to…
- Trial name
- NCT05636436
- Testing
- Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster, Electroacupuncture
Electroacupuncture Regulation of Immune Cells in Herpes Zoster
Herpes Zoster (HZ), caused by the Varicella-Zoster Virus (VZV), is a common infection characterized by localized pain and blistering, with higher incidence in females.
- Conditions
- Herpes Zoster, Electroacupuncture, Immune
- Trial name
- NCT06643247
- Testing
- Drug, Electroacupuncture
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Hangzhou